PEPTONIC medical Past Earnings Performance
Past criteria checks 0/6
PEPTONIC medical's earnings have been declining at an average annual rate of -13%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 30.5% per year.
Key information
-13.0%
Earnings growth rate
16.6%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 30.5% |
Return on equity | -57.9% |
Net Margin | -148.3% |
Next Earnings Update | 06 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How PEPTONIC medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 33 | -49 | 56 | 0 |
31 Mar 24 | 39 | -45 | 56 | 0 |
31 Dec 23 | 37 | -43 | 52 | 0 |
30 Sep 23 | 41 | -31 | 48 | 0 |
30 Jun 23 | 43 | -32 | 49 | 0 |
31 Mar 23 | 44 | -34 | 51 | 0 |
31 Dec 22 | 44 | -37 | 56 | 0 |
30 Sep 22 | 39 | -74 | 69 | 0 |
30 Jun 22 | 34 | -75 | 69 | 0 |
31 Mar 22 | 29 | -78 | 69 | 0 |
31 Dec 21 | 32 | -74 | 65 | 0 |
30 Sep 21 | 33 | -40 | 55 | 0 |
30 Jun 21 | 35 | -37 | 54 | 0 |
31 Mar 21 | 31 | -32 | 48 | 0 |
31 Dec 20 | 21 | -31 | 42 | 0 |
30 Sep 20 | 14 | -30 | 36 | 0 |
30 Jun 20 | 7 | -27 | 28 | 0 |
31 Mar 20 | 5 | -26 | 25 | 0 |
31 Dec 19 | 4 | -25 | 24 | 0 |
30 Sep 19 | 4 | -20 | 19 | 0 |
30 Jun 19 | 3 | -19 | 18 | 0 |
31 Mar 19 | 2 | -17 | 15 | 0 |
31 Dec 18 | 0 | -15 | 14 | 0 |
30 Sep 18 | 0 | -15 | 13 | 0 |
30 Jun 18 | 0 | -14 | 12 | 0 |
31 Mar 18 | 0 | -13 | 11 | 0 |
31 Dec 17 | 0 | -13 | 11 | 0 |
30 Sep 17 | 0 | -11 | 10 | 0 |
30 Jun 17 | 0 | -10 | 9 | 0 |
31 Mar 17 | 0 | -10 | 9 | 0 |
31 Dec 16 | 0 | -11 | 10 | 0 |
30 Sep 16 | 0 | -13 | 13 | 0 |
30 Jun 16 | 0 | -14 | 14 | 0 |
31 Mar 16 | 0 | -15 | 15 | 0 |
31 Dec 15 | 0 | -14 | 14 | 0 |
30 Sep 15 | 0 | -13 | 6 | 0 |
30 Jun 15 | 0 | -13 | 6 | 0 |
31 Mar 15 | 0 | -12 | 4 | 0 |
31 Dec 14 | 0 | -10 | 3 | 0 |
30 Sep 14 | 0 | -8 | 4 | 0 |
30 Jun 14 | 0 | -7 | 3 | 0 |
31 Mar 14 | 0 | -5 | 2 | 0 |
Quality Earnings: 28L is currently unprofitable.
Growing Profit Margin: 28L is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 28L is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare 28L's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 28L is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 28L has a negative Return on Equity (-57.86%), as it is currently unprofitable.